According to CRISPR Therapeutics's latest financial reports the company's current EPS (TTM) is -5,36ย โฌ. In 2025 the company made an earnings per share (EPS) of -5,62ย โฌ a decrease over its 2024 EPS that were of -3,77ย โฌ.